Skye Bioscience Inc.

Skye will be presenting at the upcoming J.P. Morgan Healthcare conference on Thursday, January 16th at 10:30am-11:10am PT. The live and archived webcast will be accessible on our website. Read the full article here: https://bit.ly/3Dje3wU

The Skye team has wrapped up two busy weeks of conferences. You can find webcasts below: Guggenheim Healthcare Conference (fireside chat): https://bit.ly/3ACtgbG UBS Healthcare Conference (fireside chat): https://bit.ly/490R4Cv Stifel Healthcare Conference (presentation): https://bit.ly/4i0lbyj

Skye looks forward to rounding out a busy conference year by participating in these upcoming healthcare investment conferences. All webcasts will be accessible on our website. Read the full article here: https://bit.ly/4hR0Uer

Skye expects to report interim data for the CBeyond™ Phase 2 clinical trial in Q2 2025 after this initial set of enrolled patients has completed the 26-week treatment period. Read the full article here: https://bit.ly/3URs0bx

Skye hosted a satellite presentation on Nov. 5th during ObesityWeek 2024. Discover how Skye's drug, nimacimab, stands out by achieving effective peripheral CB1 inhibition without central exposure (and its risk of neuropsychiatric adverse events), leading to powerful benefits: dose-dependent weight loss, fat mass reduction with lean mass preservation, and improved glycemic control. Watch our full presentation here: https://lnkd.in/gxx2PbdP

Preliminary data from Skye's newly-developed diet-induced obesity (DIO) model in mice fulfilled its initial objective of showing that peripheral CB1 inhibition achieves significant weight loss without relying on central activity and its risk of neuropsychiatric adverse events. Skye’s peripherally-targeting antibody, nimacimab, a CB1 inverse agonist and antagonist, achieved dose-dependent weight loss of up to 16% compared to vehicle. Read the full article here: https://bit.ly/4fQ49B9

We are looking forward to participating in upcoming healthcare conferences. Available webcasts will be accessible on our website. Click here to read the full article: https://bit.ly/3YAsgwH

“It is clear that with increased restriction from the brain, nimacimab provides a potential safety advantage over a small molecule approach..." Skye CEO, Punit Dhillon said. Read the full article here: https://bit.ly/47EeaOX

We are looking forward to our formal presentation and investor meetings at #CantorHCC where Punit and Puneet will be representing Skye. View the webcast live on Sept 19 at 8:35am ET or the archive: https://lnkd.in/gRxa-jea

Skye looks forward to its fireside chat and meetings at Morgan Stanley on Friday, September 6th at 1:50 pm ET. Join the Webcast here, or watch the archived version: https://lnkd.in/gkFax6_C #MSHealthcare